Verzenio — United Healthcare
Endometrial carcinoma
Initial criteria
- Diagnosis of recurrent or metastatic endometrial cancer
- Tumor is estrogen receptor (ER)-positive
- Used in combination with letrozole
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Verzenio therapy
Approval duration
12 months